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Abstract
More than 800 published genetic association studies have implicated dozens of potential risk loci in Parkinson’s disease (PD). To
facilitate the interpretation of these findings, we have created a dedicated online resource, PDGene, that comprehensively collects
and meta-analyzes all published studies in the field. A systematic literature screen of,27,000 articles yielded 828 eligible articles
from which relevant data were extracted. In addition, individual-level data from three publicly available genome-wide association
studies (GWAS) were obtained and subjected to genotype imputation and analysis. Overall, we performedmeta-analyses onmore
than seven million polymorphisms originating either from GWAS datasets and/or from smaller scale PD association studies. Meta-
analyses on 147 SNPs were supplemented by unpublished GWAS data from up to 16,452 PD cases and 48,810 controls. Eleven loci
showed genome-wide significant (P,561028) association with disease risk: BST1, CCDC62/HIP1R, DGKQ/GAK, GBA, LRRK2, MAPT,
MCCC1/LAMP3, PARK16, SNCA, STK39, and SYT11/RAB25. In addition, we identified novel evidence for genome-wide significant
association with a polymorphism in ITGA8 (rs7077361, OR 0.88, P=1.361028). All meta-analysis results are freely available on a
dedicated online database (www.pdgene.org), which is cross-linked with a customized track on the UCSC Genome Browser. Our
study provides an exhaustive and up-to-date summary of the status of PD genetics research that can be readily scaled to include
the results of future large-scale genetics projects, including next-generation sequencing studies.
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Introduction
Parkinson’s disease (PD) is the second most common neurode-
generative disease with a prevalence of ,1% over 60 years of age
[1]. Approximately 5–10% of the patients show an autosomal
dominant or recessive mode of inheritance, and several causative
genes have been identified, e.g. SNCA, LRRK2, PARK2, and PINK1
(for review see ref. [2]). Recently, two other novel autosomal
dominant PD genes, VPS35 and EIF4G1 [3–5], have been
identified, the former via application of next-generation sequencing
techniques. It can be anticipated that causal mutations in additional
genes will emerge within the next years. However, the vast majority
of patients suffer from non-Mendelian forms of PD, which are likely
caused by the combined effects of genetic and environmental
factors. In order to decipher the genetic architecture underlying PD
susceptibility, more than 800 genetic association studies have been
performed over the past 20 years. While early candidate gene
studies and subsequent meta-analyses provided conclusive evidence
showing that polymorphisms in SNCA [6] (encoding alpha-
synuclein), LRRK2 [7] (leucine-rich repeat kinase 2), MAPT [8]
(microtubule-associated protein tau), and GBA [9] (acid beta-
glucosidase) significantly impact PD susceptibility, most association
studies in the field provided inconclusive or even conflicting results.
During the last few years, genome-wide association studies
(GWAS) [10–19] have postulated additional PD loci. While the
early GWAS and a GWAS-meta-analysis [20] were of limited
sample sizes and yielded mostly inconsistent results, more recent
studies have identified a number of loci that were independently
confirmed in follow-up studies (e.g. GAK, BST1, and PARK16, see
Table 1 for all proposed GWAS findings across GWAS
publications). Very recently, a GWAS meta-analysis [21] impli-
cated several other new putative PD loci which currently await
further validation. Despite this progress, approximately 40% or
more of the population-attributable risk probably remains
unexplained by today’s most promising PD loci [21]. To this
end, genetic association studies remain one of the mainstays of PD
genetics research. However, GWAS and other large-scale
association studies typically only highlight the most promising
results and often do not provide data on variants showing
suggestive evidence for association, or previously implied variants
that could not be confirmed in the GWAS setting. As a result, the
cumulative genetic evidence in favor of or against association with
certain variants in the PD field is becoming increasingly difficult to
follow, evaluate and interpret. To address this problem, we have
comprehensively collected, catalogued and systematically meta-
analyzed the data from all genetic association studies published in
the field of non-Mendelian PD, including GWAS, and made all
results publicly available on a regularly updated online database,
‘‘PDGene’’ (http://www.pdgene.org).
Results
Database content
The results of this research synopsis are based on a freeze of the
PDGene database content on March 31st 2011 (available upon
request from the authors). At that time, PDGene included details
on 828 individual studies across more than 50 different countries
and six continents reporting on 3,382 polymorphisms in 890
genetic loci. Data for more than 2,000 SNPs were supplemented
by results derived from up to three publicly available GWAS
datasets [10,12,13] following extensive quality control and
imputation. Ultimately, this procedure yielded a total of 867
polymorphisms across ,300 genetic loci that met our criteria for
meta-analysis (see Methods). Additional independent GWAS data
The PDGene Database
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for 147 SNPs yielding P values of #0.1 in these initial meta-
analyses were provided by researchers of all remaining currently
published Caucasian GWAS datasets [13,15–19,22]. Following
the identification of genome-wide significant association with an
intronic SNP (rs7077361) in ITGA8 after addition of these data, we
obtained additional data from the same GWAS datasets on
,1,400 SNPs in the chromosomal region encompassing ITGA8
(chr10:15346353–15801533, hg18). Finally, independent replica-
tion data in Caucasian and Asian populations from the GEO-PD
consortium [23] generated for ten recently described PD loci [21]
were made available for inclusion. As a result, we were able to
substantially increase the sample size (up to 16,452 PD cases and
48,810 controls) for a large number of some of the most promising
PD loci. For instance, we were able to add data from up to 48,861
previously not analyzed combined cases and controls to meta-
analyses of some of the recently proposed PD loci [21] (median
sample size 14,896, see Table 2 and Table S1 for details). In
addition to these focused analyses, PDGene displays meta-analysis
results for more than seven million additional SNPs originating
from up to three publicly available GWAS datasets [10,12,13].
The results are available online (e.g. as summarized in http://
www.pdgene.org/largescalemeta.asp), where they are cross-linked
to a customized and fully browsable track on the UCSC Genome
Browser.
PDGene meta-analysis results
The PDGene meta-analyses of the 867 core polymorphisms were
based on a median of 7,680 subjects (interquartile range 4,612–
16,726). Additional meta-analyses were performed after stratifica-
tion for Caucasian and Asian ancestry (for details on sample size and
included ethnicities for individual meta-analyses see Table S1). In
addition, we also performed random-effects meta-analyses across all
three publicly available GWAS datasets [10,12,13] following
genotype imputation using data from the International HapMap
Consortium and 1000 Genomes Project. Ultimately this yielded
7,123,920 SNPs that could be meta-analyzed across at least two
GWAS datasets (see Figure S1 for a quantile-to-quantile plot of the
GWAS-only meta-analyses). All 867 core meta-analysis results are
available online on PDGene as forest plots, summarizing the relative
contributions of each dataset to the most current summary effect
estimate, and in the form of cumulative plots, illustrating how
summaryORs evolve over time. All meta-analysis results are plotted
in Figure 1 (green dots) alongside the GWAS-only meta-analysis
results (black and grey dots).
One-hundred-three meta-analyses across 12 genetic loci (BST1,
CCDC62/HIP1R, DGKQ/GAK, GBA, ITGA8, LRRK2, MAPT,
MCCC1/LAMP3, PARK16, SNCA, STK39, SYT11/RAB25) yield-
ed summary ORs suggesting a genome-wide significant
(P#561028) increase or decrease in PD risk in all ethnicities
and/or after stratification for ethnic ancestry (Table 2, Table S1,
and Figure S2 [forest plots]). None of these loci contained more
than one SNP independently associated at genome-wide signifi-
cance (as judged by pair-wise linkage disequilibrium assessments
using ‘SNAP’ and r2-values of 0.2 as cut off http://www.
broadinstitute.org/mpg/snap/). The majority of polymorphisms
tested in the genome-wide significant loci do not show evidence for
publication bias (Table S1). Finally, all genome-wide significant
signals were robust against potential undetected sample overlap
using a recently proposed procedure [24] (see Table S2 for more
details). Combined sample sizes for all 12 loci were substantially
larger here as compared to any previously published meta-analysis
(Table S1), providing unequivocal evidence for an involvement of
these loci in PD susceptibility. While power to detect genome-wide
significance was excellent for most of these loci (.80% based on
an OR of 1.15, and a minor allele frequency down to 0.05 using
the Genetic Power Calculator, http://pngu.mgh.harvard.edu/
,purcell/gpc/), power was less for a large number of other meta-
analyses due to smaller sample sizes and allele frequencies (see
Table S1 for details). Thus, no simple statistic can summarize the
overall power of our study.
The above list includes an intronic polymorphism in ITGA8
located on chromosome 10p13 for which we identified novel
evidence for genome-wide association with PD risk (OR 0.88,
P=1.361028, I2 = 0, see Table 2, and Figure 2). This SNP had
previously been proposed to be associated with PD risk at sub-
genome-wide significance by Simon-Sanchez et al [13]. After
obtaining and meta-analyzing GWAS data from ,1,400 addi-
tional SNPs in this region derived from all Caucasians GWAS
datasets [10,12,13,15–19,21,22], rs7077361 remained the most
significantly associated SNP in this region (Figure S3).
In addition to using random-effects models, we also performed
exploratory fixed-effect meta-analyses on all eligible polymor-
phisms. These analyses did not reveal genome-wide significant
effect sizes for any additional locus, except ACMSD/TMEM163
(most significant SNP rs6723108, OR 0.91, P=1.361029,
I2 = 46% [95% CI 0–73%], Figure S4, panel 1) and HLA (most
significant SNP chr6:32609909, OR 0.78, P=8.8610215,
I2 = 84% [95% CI 70–91%], Figure S4, panel 2), both of which
were reported to be associated with PD risk at genome-wide
significance in previous work [16,21]. In both instances, the lack of
genome-wide significance in the random-effects models (Table S1)
was due to relatively pronounced heterogeneity of effect estimates
across studies. However, the heterogeneity across the 11 datasets
in the ACMSD/TMEM163 meta-analysis is almost entirely due to
variance of effect size estimates in the same direction (see Figure
S4, panel 1), making it likely that ACMSD/TMEM163 represents a
genuine PD risk locus. For the SNP tested in the HLA locus
(chr6:32609909, Figure S4, panel 2), heterogeneity is more
pronounced and more complex owing to ORs on either side of
Author Summary
The genetic basis of Parkinson’s disease is complex, i.e. it is
determined by a number of different disease-causing and
disease-predisposing genes. Especially the latter have
proven difficult to find, evidenced by more than 800
published genetic association studies, typically showing
discrepant results. To facilitate the interpretation of this
large and continuously increasing body of data, we have
created a freely available online database (‘‘PDGene’’:
http://www.pdgene.org) which provides an exhaustive
account of all published genetic association studies in
PD. One particularly useful feature is the calculation and
display of up-to-date summary statistics of published data
for overlapping DNA sequence variants (polymorphisms).
These meta-analyses revealed eleven gene loci that
showed a statistically very significant (P,561028; a.k.a.
genome-wide significance) association with risk for PD:
BST1, CCDC62/HIP1R, DGKQ/GAK, GBA, LRRK2, MAPT,
MCCC1/LAMP3, PARK16, SNCA, STK39, SYT11/RAB25. In
addition and purely by data-mining, we identified one
novel PD susceptibility locus in a gene called ITGA8
(rs7077361, P= 1.361028). We note that our continuously
updated database represents the most comprehensive
research synopsis of genetic association studies in PD to
date. In addition to vastly facilitating the work of other PD
geneticists, our approach may serve as a valuable example
for other complex diseases.
The PDGene Database
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1. This could be due to a number of reasons, e.g. subtle and
uncorrected population substructure and/or different LD patterns
between the analyzed SNP and the actual functional variant(s)
[16]. Thus, although the evidence is currently not as conclusive as
for ACMSD/TMEM163 it still appears quite possible that there is
one or more PD association signals in the HLA region. Regardless
of these considerations, additional data are needed to more firmly
assess the role of both loci in contributing to PD susceptibility.
Ethnicity-specific meta-analysis results
SNCA, LRRK2, BST1, and PARK16 show evidence for genome-
wide significance in meta-analyses restricted to Caucasian and
Asian populations (Table 2). Furthermore, data obtained from the
GEO-PD consortium [23] suggest that the effect estimates for
some of the recently discovered PD loci (i.e. CCDC62/HIP1R,
MCC1, and STK39) [21] may be comparable in Caucasian and
Asian populations (Table S1), although additional datasets are
needed to establish genome-wide significance in populations of
Asian-descent for these loci. Conversely, only insufficient data are
currently available to assess the effect sizes of GAK and SYT11/
RAB25 on PD risk in Asians: GAK rs6599388 violated Hardy-
Weinberg equilibrium in Asian datasets from the GEO-PD
consortium and was thus excluded from further analyses on that
ethnic group [23]. SYT11/RAB25 chr1:154105678 was excluded
from all analyses due to technical reasons in the study by the
GEO-PD consortium [23]. Moreover, none of the reported
SYT11/RAB25 and GAK SNPs from the recent GWAS meta-
analysis [21] were captured directly or by proxy (with an r2$0.8)
in the Japanese GWAS dataset [14,23]. Finally, Asian-descent
populations cannot be appropriately assessed for PD association
with the MAPT-H1/H2 haplotype, rs10928513 in ACMSD, and
rs7077361 in ITGA8 owing to monomorphicity at these sites
[14,23].
Evaluating the credibility of significant associations
To estimate the epidemiologic credibility of associations with
polymorphisms showing sub-genome-wide significant association
with PD (P.561028), we applied two ‘‘credibility’’ measures for
each such result. First, we calculated Bayes factors (BF, expressed
here as log10-values, ‘‘logBF’’) assuming an average non-null odds
ratio of 1.15, as approximation of a typical ‘‘complex disease effect
size’’, and a spike and smear prior distribution of effects [25]. Our
Table 1. Overview of genome-wide association studies (GWAS) published in PD until March 31, 2011.
GWAS
Design GWAS
(Follow-up)
Population GWAS
(Follow-up) # SNPs
# PD GWAS
(Follow-up)
# CTRL GWAS
(Follow-up)
‘‘Featured’’
genetic loci
Maraganore, 2005 (ref. 9) Family-based (case-
control)
USA-LEAPS (USA) 198,345 443 (332) 443 (332) CDCP2, GALNT3,
GWA_2q36.3,
GWA_4q28.1,
GWA_4q28.3,
GWA_5p15.32,
GWA_7p14.2,
GWA_10q21.1, PASD1,
PRDM2, SEMA5A
Fung, 2006 (ref. 10) Case-control (-) USA-NINDS 408,803 267 (-) 270 (-) BRDG, DLG2,
GLT25D2,
GWA_4q35.2,
GWA_7p12,
GWA_10q11.21,
GWA_11q11,
GWA_16q23.1,
GWA_22q13, NEGR1,
ULK2, ZNF313
Pankratz, 2009 (ref. 11) Case-control (-) USA-PROGENI/GenePD (-) 328,189 857 (-) 867 (-) DGKQ/GAK, GPRIN3,
MAPT, SNCA
Simon-Sanchez, 2009 (ref. 12) Case-control
(case-control)
USA-NINDS, Germany
(USA, Germany, UK)
463,185 1,745 (3,452) 4,047 (4,756) LRRK2, MAPT,
PARK16, SNCA
Satake, 2009 (ref. 13) Case-control
(case-control)
Japan (Japan) 435,470 1,078 (993) 2,628 (15,753) BST1, LRRK2,
PARK16, SNCA
Edwards, 2010 (ref. 14) Case-control (-) USA-HIHG (-) 491,376 604 (-) 619 (-) MAPT, SNCA
Hamza, 2010 (ref. 15) Case-control (-) USA-NGRC (-) 811,597 2,000 (-) 1,986 (-) GAK/DGKQ, HLA
locus, MAPT, SNCA
Spencer, 2011 (ref. 16) Case-control
(case-control)
UK-WTCCC2 (France) 1,733,533 1,705 (1,039) 5,175 (1,984) BST1, GAK/DGKQ,
MAPT, PARK16,
SNCA
Saad, 2011 (ref. 17) Case-control
(case-control)
France (UK-WTCCC2,
Australia)
492,929 1,039 (3,232) 1,984 (7,064) BST1, GWA_12q24,
SNCA
Simon-Sanchez, 2011 (ref. 18) Case-control
(case-control)
Netherlands 514,799 772 (-) 2024 (-) BST1, HLA locus,
GAK/DGKQ, MAPT,
SNCA
The overview is based on content on the PDGene website (http://www.pdgene.org; current on March 31st, 2011). Studies are listed in order of publication date. ‘# PD
GWAS’ and ‘# CTRL GWAS’ refers to sample sizes used in the initial GWAS datasets, whereas ‘Follow-up’ refers to the total number of replication samples where
applicable. ‘Featured genes’ are those genes/loci that were declared as ‘associated’ in the original publication; note that criteria for declaring association varies across
studies. Genetic loci in bold font denote genes showing genome-wide significant results (P,561028) in the PDGene meta-analyses.
doi:10.1371/journal.pgen.1002548.t001
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second assessment was based on the Human Genome Epidemi-
ology Network’s (HuGENet) interim criteria for the assessment of
cumulative epidemiologic evidence in genetic association studies
[26,27]. The results of these analyses are summarized in Table S1.
There was strong epidemiologic support in both assessments
for all loci showing genome-wide significant association. This
included several additional polymorphisms in these same loci that
only showed sub-genome-wide significant association. However,
there was no additional sub-genome-wide significantly associated
locus that received unequivocally strong support from both
credibility assessments (Table S1). In this list, the strongest
support was assigned to SNP chr6:32588205 in the HLA locus
receiving the best possible grade in the HuGENet criteria (grade
A), but more moderate support in the Bayesian analyses
(logBF= 4.4). However, the relevance of this assessment needs
to be evaluated as the underlying analysis was only based on four
GWAS datasets.
Discussion
The PDGene database represents a comprehensive, regularly
updated and freely available online research synopsis of genetic
association studies in PD. Detailed summaries of the most
compelling findings are provided within an easy-to-use, dedicated
online framework, displaying forest plots, cumulative meta-
analyses, and an up-to-date ranking of ‘‘Top Results’’. To allow
comparison of PDGene results with association findings from
other complex diseases and to facilitate their interpretation with
respect to functional genetics data, all meta-analysis results have
been ported as a customized track onto the UCSC Genome
Browser. This will also allow for a integration and visualization
[28] of association results from large-scale resequencing data (e.g.
from whole-exome or whole-genome studies) into PDGene once
these become available.
To the best of our knowledge, our study represents the most
comprehensive research synopsis in the field of PD genetics. In
addition, it represents the first disease-specific genetic database
that allows a systematic and exhaustive inclusion of GWAS data,
and may serve as a model for similar databases in other complex
genetic diseases. Owing to our multi-pronged data retrieval and
analysis protocol we were able to perform meta-analyses on the
vast majority of PD risk-gene candidates, including those
‘‘featured’’ as top association results in all published GWAS. In
particular, this includes the five novel loci recently featured in the
recent GWAS meta-analysis [21]. Through collaboration with
other PD genetics laboratories we obtained independent summary
data for these and 142 additional SNPs, substantially extending
the hitherto available evidence. Taken together, our analyses
provide unequivocal evidence that BST1, CCDC62/HIP1R,
DGKQ/GAK, GBA, ITGA8, LRRK2, MAPT, MCCC1/LAMP3,
PARK16, SNCA, STK39, SYT11/RAB25 represent genuine PD
risk loci, while the role of several other loci (e.g. ACMSD/
Table 2. Genome-wide significant summary meta-analysis results of the PDGene database in populations of Caucasian and Asian
decent.
Caucasian ethnicity
Locus Polymorphism Location (hg18) MAF
Allele
contrast
N
datasets N samplesOR (95% CI) P-value I2 (95% CI) HuGENet BF
GBA N370S chr1:153451576 0.01 G vs. A 15 44,851 3.51 (2.55–4.83) 1.44610214 38 (0–66) A 6.6
SYT11/RAB25 chr1:154105678 chr1:154105678 0.02 T vs. C 6 17,300 1.73 (1.48–2.02) 2.35610212 0 (0–52) B* 8.2
PARK16 rs947211 chr1:204019288 0.23 A vs. G 12 69,262 0.91 (0.88–0.94) 8.00610210 0 (0–66) A 6.8
STK39 rs2390669 chr2:168800188 0.13 C vs. A 14 35,159 1.19 (1.12–1.25) 1.37610209 18 (0–56) A 4.9*
MCCC1/LAMP3 rs11711441 chr3:184303969 0.14 A vs. G 25 46,502 0.86 (0.82–0.91) 9.20610210 18 (0–50) A 6.8
DGKQ rs11248060 chr4:954359 0.12 T vs. C 10 57,716 1.21 (1.15–1.27) 3.04610212 11 (0–52) A 9.2
BST1 rs11724635 chr4:15346199 0.43 C vs. A 26 46,586 0.88 (0.84–0.91) 1.87610210 43 (10–64) A 7.5
SNCA rs356219 chr4:90856624 0.41 G vs. A 31 79,494 1.29 (1.25–1.33) 6.06610265 16 (0–46) A 61.0
ITGA8 rs7077361 chr10:15601549 0.12 C vs. T 11 61,036 0.88 (0.84–0.92) 1.51610208 0 (0–55) A 5.7
LRRK2 rs1491942 chr12:38907075 0.21 G vs. C 21 34,123 1.17 (1.13–1.22) 6.44610215 0 (0–38) A 11.8
CCDC62/HIP1R rs10847864 chr12:121892551 0.39 T vs. G 23 38,367 1.15 (1.11–1.18) 4.37610217 0 (0–35) A 14.4
MAPT/STH H1H2 chr17:42131818–
41149582
0.20 H2 vs. H1 37 50,389 0.78 (0.75–0.80) 7.97610252 0 (0–29) A 48.1
Asian ethnicity
Locus PolymorphismLocation (hg18)MAF Allele contrast N datasets N samples OR (95% CI) P-value I2 (95% CI) HuGENet BF
PARK16 rs823156 chr1:204031263 0.17 G vs. A 5 22,870 0.74 (0.68–0.81) 2.09610212 0 (0–58) A 9.2
BST1 rs4538475 chr4:15347035 0.38 G vs. A 3 20,393 0.80 (0.75–0.86) 9.53610210 0 (-) A 6.8
SNCA rs6532194 chr4:90999925 0.40 T vs. C 5 22,844 1.29 (1.20–1.39) 4.91610211 31 (0–74) A 8.0
LRRK2 rs34778348 chr12:39043595 0.04 A vs. G 13 10,441 2.23 (1.89–2.63) 2.97610221 0 (0–53) B* 15.2
Whenever multiple polymorphisms showed genome-wide significant association in the same locus, only the variant with the smallest P-value is listed here. Note that,
overall, 103 PDGene meta-analyses results across the 12 loci listed above yield genome-wide significant evidence for association with PD. For a complete list of these as
well as the non-genome-wide significant meta-analysis results performed for the datafreeze, see Table S1. MAF =minor allele frequency in cases and controls combined;
N=Number, OR =Odds Ratio; CI = confidence interval; I2 = estimate of percentage of between-study heterogeneity that is beyond chance. BF = Bayes factor. *Note that
additional polymorphisms in these loci showing genome-wide significant association with PD yield are graded with ‘‘strong epidemiologic credibility’’ (grade A)
according to the HuGENet criteria [26,27], and a Bayes Factor .5 [25], respectively (see Table S1 for more details).
doi:10.1371/journal.pgen.1002548.t002
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TMEM163, and the HLA locus) remains to be determined. The
unpublished data aggregated here from various PD genetics
groups for selected candidate genes represents the first step
towards a systematic meta-analysis across the full GWAS datasets
from the same populations. Once completed, the results of this
‘‘mega’’ meta-analysis will be posted on the PDGene database,
allowing users to browse the complete results via the customized
genome browser track already in place.
Figure 1. Manhattan plot of all meta-analysis results performed in PDGene. This summary combines association results from 7,123,986
random-effects meta-analyses based on the March 31st 2011 datafreeze of the PDGene database. Results are plotted as 2log10 P-values (y-axis)
against physical chromosomal location (x-axis). Black and grey dots indicate results originating exclusively from the three fully publicly available
GWAS datasets [10,12,13] (see Methods), while green dots are based on a combination of smaller scale studies, supplemented by GWAS datasets
(where applicable). Gene annotations are provided for genes highlighted in the main text.
doi:10.1371/journal.pgen.1002548.g001
Figure 2. Forest plot of the meta-analysis of rs7077361 in ITGA8. Study-specific allelic odds ratios (ORs, black squares) and 95% confidence
intervals (CIs, lines) were calculated for each included dataset. The summary OR and CI was calculated using the DerSimonian Laird random-effects
model (grey diamond) [31]. C =Caucasian ancestry.
doi:10.1371/journal.pgen.1002548.g002
The PDGene Database
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Of particular interest are loci with unusually large effect sizes.
While most loci in PDGene have only small effects on PD risk (with
ORs ranging from 1.10 to 1.35, which are typical for complex
diseases), for some loci much larger ORs were estimated (i.e. GBA
[OR 3.51 in Caucasians], LRRK2 [OR 2.23 in Asians], and SYT11/
RAB25 [OR 1.73 in Caucasians], see Table 2). The risk-allele
frequencies at these polymorphisms are typically rather small (i.e.
below 0.05), resulting in low population attributable risks for these
loci (for the above mentioned loci individually less than 2%).
Interestingly, the meta-analysis results of GBA N370S as well as
the LRRK2 rs34778348 are solely based on candidate-gene
approaches since these SNPs are not on any of the current
GWAS arrays or imputation reference panels. Thus, even in the
‘‘GWAS era’’ smaller-scale, non-GWAS but ‘‘focused’’ genetic
studies, will likely continue to play an important role. This is also
true when it comes to providing independent replication of
proposed disease associations and/or when validating imputation-
derived results by direct genotyping in sufficiently sized datasets.
PDGene systematically concatenates all these different types of
data into one database framework, vastly facilitating an assessment
of the overall evidence for any given SNP or locus.
The strength of our approach is further exemplified by the
identification of genome-wide significant association between
disease risk and a SNP in ITGA8, which was not featured as a
relevant PD gene in any previous study. ITGA8 (encoding integrin
alpha 8, a type-I transmembrane protein) is functionally
interesting as it is expressed in brain [29], mediates cell-cell
interactions and regulates neurite outgrowth of sensory and motor
neurons [30]. Additional studies are needed to further assess the
potential role of this gene in PD pathogenesis. Furthermore,
PDGene shows that two additional loci, not highlighted by the
recent GWAS meta-analysis [21], yield genome-wide signficiant
results in the PDGene meta-analyses, i.e. PARK16, originally
implicated as a PD susceptibility locus in an Asian GWAS [14] but
not highlighted in the recent GWAS meta-analysis on Caucasian
samples [21] and GBA, a gene that was found soley by candidate-
gene approaches. Another strength of our study is that it combines
genetic data from currently more than 50 different countries
allowing a systematic assessment of genetic associations across
populations of different ethnic descent. For instance, these analyses
suggest that variants in BST1, LRRK2, the PARK16 locus, and
SNCA show genome-wide significant association with PD risk in
both Caucasian and Asian-descent samples. Furthermore, the
recently described Caucasian GWAS loci CCDC62/HIP1R,
MCC1, and STK39 [21] also show similar effect size estimates in
populations of Asian-descent [23]. PD association data originating
from other ethnic groups are still relatively scarce. However, they
could easily be added to the already existing data on the respective
polymorphisms available on PDGene.
In summary, we have created a continuously updated online
resource for genetic association studies in the field of PD.
Synthesizing essentially all available data in the field led to the
identification of ITGA8 as a novel potential PD risk locus. Our
quantitative approach to data integration across a multitude of
different study designs can be readily scaled to include large-scale
resequencing efforts that will emerge over the coming years,
making the complex field of PD genetics accessible to a broad
range of investigators.
Methods
Note that the following section only provides a brief summary of
the methods applied to our study. A much more detailed
description can be found in Text S1.
Literature searches
Inclusion criteria. For inclusion in PDGene, a study has to
meet three criteria: 1) It must evaluate the association between a
bi-allelic genetic polymorphism (minor allele frequency $0.01 in
the healthy control population of at least one study) and
Parkinson’s disease (PD) risk in datasets comprised of both
affected (defined as clinically and/or neuropathologically
diagnosed ‘‘Parkinson’s disease’’) and unaffected individuals; 2) it
must be published in a peer-reviewed journal; 3) it must be
published in English. For this manuscript, we also included data
on ten SNPs generated in the GEO-PD Consortium datasets
[14,23] and obtained data for the newly identified SNP rs7077361
in ITGA8 from the Japanese GWAS dataset [14].
Exclusion criteria. In brief, genetic association data of the
following studies were excluded from the meta-analyses (see Text
S1 for details): family-based studies without available subject-level
data (however, unrelated case-control data enriched for familial
cases were not excluded), studies investigating only disease
controls, multi-allelic polymorphisms, and studies of
polymorphisms in mitochondrial DNA. We also excluded
genetic data of apparently ‘‘poor’’ quality if discrepancies could
not be resolved after contacting the study authors (e.g. inadequate
genotyping/sequencing protocols or discrepancies in terms of
allele names or frequencies when compared with public databases;
more details can be found in Text S1).
Search strategies. Our literature searches until March 31st,
2011, yielded 27,210 articles, which were screened for eligibility
using the title, abstract, or full-papers, as necessary. Additional
screening of bibliographies in reviews, published meta-analyses,
and original genetic association studies were also performed.
Overall, full text versions of 1,534 articles were obtained.
Following the inclusion and exclusion criteria outlined above,
828 articles were included in PDGene until March 31st 2011 (also
see Figure 3).
Statistical analyses
Meta-analyses. Random-effects allelic meta-analyses [31]
were performed if a minimum of four independent datasets
existed per polymorphism. Summary odds ratios [ORs] and 95%
confidence intervals [CIs] were calculated irrespective of ethnic
descent as well as for distinct ethnic groups (i.e. Caucasians, and
Asians) if sufficient data were available. In addition, we performed
a number of sensitivity analyses (excluding the initial studies and
datasets in which HWE was violated in control individuals),
systematically assessed between-study heterogeneity (via I2), and
assessed the credibility of each at least nominally significant meta-
analysis result by calculating Bayes factors (BF; here expressed as
log10(BF) = ‘‘logBF’’) [25] and by determining a grading score
developed by the Human Genome Epidemiology Network
(HuGENet) [26,27].
Assessment of small-study bias/publication bias. This is
of particular importance in meta-analyses of published association
data and was carefully addressed here: First, we added publicly
available GWAS data [10,12,13] to the vast majority of SNPs.
Since these data are typically unbiased, this should decrease the
potential for small-study bias/publication bias. Secondly, for 147
SNPs of the core PDGene meta-analyses that showed statistically
suggestive results (P#0.1), we obtained additional data from all
currently published, but not publicly available GWAS datasets,
further decreasing a potential impact of small-study bias/
publication bias. Thirdly, we directly assessed the evidence for
small study bias by applying a recently proposed regression test
[32] on all nominally significant (P,0.05) meta-analysis results.
The results of these analyses are fully displayed in Table S1.
The PDGene Database
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GWAS-only meta-analyses. We obtained individual-level
genotype data for all publicly available PD GWAS datasets from
NCBI’s ‘‘dbGAP’’ database (a total of three [10,12,13] at the time
of the datafreeze, March 31st, 2011). Genotype data were cleaned
using standard procedures, followed by imputation of untested
genotypes (using reference panels from HapMap and the 1000
Genomes Project), and association analyses incorporating
imputation uncertainty (case-control datasets only), age, sex, and
population stratification. Overall, this procedure led to a total of
7,723,931 unique SNPs, 7,123,920 of which were present in at
least two, and 711,271 in at least three datasets. Meta-analyses
(either combining test-statistics and standard errors using random-
effects models, or by combining P-values weighted by sample size,
see Text S1 for more details) were performed on the 7,123,920
SNPs present in at least two of the GWAS datasets.
Online database
After completion of all data-management and analysis steps, all
study-specific variables, genotype data (except for GWAS), and
meta-analysis plots are posted on a dedicated, publicly available,
online adaptation of the PDGene database using the same
software and code as our databases for Alzheimer’s disease [33]
and schizophrenia [34]. The online database is hosted by the
‘‘Alzheimer Research Forum’’ and can be accessed via its own
designated URL (http://www.pdgene.org).
Database code
The database software can easily be ported to other genetically
complex diseases and will be made available on a collaborative
basis to interested researchers upon request.
Supporting Information
Figure S1 QQ plots showing the distribution of expected versus
observed P-values for the GWAS-only meta-analysis results.
Analyses were performed using the METAL software (ref. [21]
in Text S1). The excess of observed P-values (Figure S1, panel 1) is
entirely due to association signals in the SNCA, MAPT, LRRK2,
and DGKQ/GAK loci as can be seen in Figure S1, panel 2 that
showcases the P-value distributions after removal of 18,622 SNPs
in these regions (lambda= 1.007).
(TIF)
Figure S2 Forest plots of allelic meta-analyses for SNPs showing
genome-wide significant association (P,561028) with PD
susceptibility in the March 31st 2011 datafreeze. Study-specific
allelic odds ratios (ORs, black squares) and 95% confidence
intervals (CIs, lines) were calculated for each included dataset.
The summary OR and CI was calculated using random-effects
models (grey diamond). Whenever multiple polymorphisms
showed genome-wide significant association in the same locus,
only the variant with the smallest P-value is listed here for meta-
Figure 3. Flowchart of literature search, data extraction, and analysis strategies applied for PDGene.
doi:10.1371/journal.pgen.1002548.g003
The PDGene Database
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analysis results after stratification for Caucasian and Asian
ancestries. For a complete list of meta-analyses performed for
the datafreeze, see Table S1. Figure S1, panel 1-S1, panel 12 and
S1, panel 13-S1, panel 16 display the SNP showing the most
significant genome-wide association in datasets of Caucasian
ancestry and Asian ancestry, respectively. Details and references
of all included studies displayed here can be found on the
PDGene database (http://www.pdgene.org). I2 = estimate of
percentage of between-study heterogeneity that is beyond chance,
‘‘excl initial’’ = summary OR and 95%CI after meta-analysis
after exclusion of the initial study, C=Caucasian ancestry,
A =Asian ancestry, H=Hispanic descent, D=African descent,
‘‘N’’ = initial study (applies to candidate-gene studies), ‘‘{’’ = no
data provided or data was not eligible for inclusion in meta-
analysis, ‘‘{’’ = study excluded due to overlap, ‘‘#’’ =HWE
violation in controls (P,0.05, not applicable to quality-controlled
GWAS datasets, see Text S1), ‘‘i’’ = SNP monomorphic in the
respective dataset, ‘‘ø’’ =meta-analysis after excluding initial
study not applicable.
(PDF)
Figure S3 Locus plot of the ITGA8 region on chromosome
10p13 (15346353–15801533 bp, hg18). The figure displays
association results for ,1,400 SNPs in the ITGA8 region including
at least four independent datasets. SNPs are color-coded based on
linkage disequilibrium (r2) estimates from the CEU 1000G dataset
(release June 2010). All LD estimates refer to the most significantly
associated SNP rs7077361. SNPs color-coded in grey indicate
missing LD estimates in the CEU dataset. Recombination rates
were estimated based on the CEU dataset, and are displayed as
blue line in the background. Gene annotations are based on
RefSeq and the UCSC Genome browser. Locus plots were
generated using the LocusZoom Stand-alone package (http://
genome.sph.umich.edu/wiki/LocusZoom_Standalone).
(TIF)
Figure S4 Forest plots of fixed-effect meta-analyses for SNP
rs6723108 in the ACMSD/TMEM163 locus and chr6:32609909
in the HLA locus. Symbols are the same as for Figure S2 (see
above).
(TIF)
Table S1 Overview of all 867 polymorphisms meta-analyzed in
the March 31st 2011 datafreeze using random-effects allelic
models. Random-effects allelic meta-analyses were performed on
polymorphisms for which four or more independent datasets were
available. Meta-analyses after stratification for different ethnic
descent were performed if at least three independent datasets were
available in the respective stratum (applicable only to samples of
European and Asian descent). Each nominally significant meta-
analysis result (P,0.05) was graded according to the HuGENet
interim criteria. For details on how these criteria are applied, see
Text S1. Meta-analysis results in this table are ordered by genomic
location. OR=Odds Ratio, CI = confidence interval, N minor=
number of minor alleles, Ethnicities: C=Caucasian, A=Asian,
D=African Descent, H=Hispanic, O=Other/Mixed, Low
OR=OR,1.15 or $0.87, respectively, F = loss of significance
in the respective meta-analysis after exclusion of the first study,
HWE= loss of significance after excluding studies violating HWE
(P,0.05), Regr = evidence for small-study/publication bias using a
modified regression test (see Text S1), A=Grade A (‘strong’
epidemiologic credibility), B =Grade B (‘modest’ epidemiologic
credibility), C=Grade C (‘weak’ epidemiologic credibility),
logBF=Bayes Factor (see Text S1). ‘‘*’’ denotes SNPs that have
been supplemented by additional data after the datafreeze (in total
this applies to 147 SNPs, see Text S1 for the description of
included datasets).
(XLS)
Table S2 Investigation of the extent of statistical inflation
assuming sample overlaps of 1%, 5%, and 10% across cases and
controls in datasets originating from the same countries.
Hypothetical sample overlap across datasets was assumed
between different candidate-gene/replication studies and be-
tween candidate-gene/replication studies and GWAS datasets if
they originated from the same country. These analyses were
performed applying random-effects models and adding the sum
of weighted co-variances of overlapping datasets to the overall
study variance (see ref. [24] in the main text). Note that the
assumption of undetected overlapping samples does not apply
(and was therefore not modeled here) to overlap between
individual GWAS as duplicate samples in these datasets were
removed prior to meta-analysis. It also does not apply to
independent datasets used in the same publication where
duplicate samples had been removed by the authors prior to
analysis and publication. We emphasize that this table describes
hypothetical scenarios, because the geographical origin of each
study had been investigated extensively and potentially overlap-
ping datasets had been excluded as part of PDGene’s data
inclusion protocol. Thus, the extent of overlap across geograph-
ically distinct datasets within the same countries is reduced to
accidental recruitment of the same subjects more than once in
different datasets throughout the respective countries, and can be
expected to be less than ,1%. This estimate is based on data of
the GEO-PD consortium, where sufficient data were centrally
available of 6,072 subjects from 20 geographically distinct sites in
13 countries that had been investigated for potentially duplicate
samples across sites, but no duplicate subjects (neither between
not within countries) were identified when matching on ethnicity,
birth, sex, and genotype. The investigation of overlap was not
applicable here for Asian datasets, as they originated from
different countries and/or were cleaned by the respective authors
prior to publication.
(DOC)
Text S1 Supplementary material. This file includes supplemen-
tary methods and references as well as the list of members of the
GWAS consortia, the GEO-PD Consortium, and consortia-
specific acknowledgements.
(PDF)
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